 |
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2025, vol. 31, issue2
Subject Area: Medicine
-
DOI: 10.5272/jimab.2025312.6179
Published online: 05 May 2025
Original article
J of IMAB. 2025 Apr-Jun;31(2):6179-6184
IS UNDERCARBOXYLATED MATRIX GLA PROTEIN A RELIABLE BIOMARKER OF VITAMIN K2 STATUS IN PATIENTS WITH CHRONIC KIDNEY DISEASE?
Tatyana Simeonova1
, Borislav Ignatov1, Tsvetelina Eftimova2, Krasimir Kostov1,
1) Department of Physiology and Pathophysiology, Faculty of Medicine, Medical University - Pleven, Bulgaria.
2) Department of Dialysis, University Hospital "Saint Marina" - Pleven, Bulgaria.
ABSTRACT:
Vitamin K2 deficiency is associated with arterial calcification, which is a significant problem in patients with chronic kidney disease. It occurs more rapidly and earlier and appears to be an independent risk factor for higher morbidity and mortality. The ucMGP is considered to be a biomarker for indirect measurement of vitamin K2 status.
Purpose: Our study aimed to measure ucMGP levels in patients at different stages of CKD and to evaluate its potential role as a biomarker of vitamin K2 status.
Material/Methods: Sixty-seven patients aged between 31 – 87 years took part in the study. They were divided into groups according to glomerular filtration rate: Group I, with GFR ≥90 ml/min, Group II, with GFR 89 – 45 ml/min, Group III, with GFR 44 – 15 ml/min. Venous blood was tested for calcium, phosphate, creatinine and ucMGP.
Results: Serum calcium and phosphate levels were within the reference ranges across all groups. Phosphate levels showed a progressive increase, with significantly lower levels in Group III. Mean ucMGP levels decreased from Group I to Group III, although these differences did not reach statistical significance. In Group I, women had significantly lower ucMGP concentrations compared to men. The incidence of CVD increased significantly with the progression of renal failure. Participants with CVD in Group I demonstrated significantly higher ucMGP concentrations compared to Group III.
Conclusions: Uncarboxylated MGP can provide information about vitamin K2 and its carboxylation, but it is not a specific or reliable marker of vitamin K2 status.
Keywords: CKD, non-dialysis patients, uncarboxylated MGP, vitamin K2,
- Download FULL TEXT /PDF 747 KB/
Please cite this article as: Simeonova T, Ignatov B, Eftimova T, Kostov K. Is Undercarboxylated Matrix Gla Protein a Reliable Biomarker of Vitamin K2 Status in Patients with Chronic Kidney Disease? J of IMAB. 2025 Apr-Jun;31(2):6179-6184. [Crossref - 10.5272/jimab.2025312.6179]
Correspondence to: Tatyana Nedkova Simeonova, Department of Physiology and Pathophysiology, Medical University-Pleven; 1, St. Kliment Ohridski Str., Pleven 5800, Bulgaria; E-mail: dr_tsimeonova@abv.bg
REFERENCES:
1. Bellone F, Cinquegrani M, Nicotera R, Carullo N, Casarella A, Presta P, et al. Role of Vitamin K in Chronic Kidney Disease: A Focus on Bone and Cardiovascular Health. Int J Mol Sci. 2022 May;23(9):5282. [PubMed]
2. Jadhav N, Ajgaonkar S, Saha P, Gurav P, Pandey A, Basudkar V, et al. Molecular Pathways and Roles for Vitamin K2-7 as a Health-Beneficial Nutraceutical: Challenges and Opportunities. Front Pharmacol. 2022 Jun 14;13:896920. [PubMed]
3. Prynne CJ, Thane CW, Prentice A, Wadsworth ME. Intake and sources of phylloquinone (vitamin K(1)) in 4-year-old British children: comparison between 1950 and the 1990s. Public Health Nutr. 2005 Apr;8(2):171-80. [PubMed]
4. Vermeer C, Drummen NEA, Knapen MHJ, Zandbergen FJ. Uncarboxylated Matrix Gla Protein as a Biomarker in Cardiovascular Disease: Applications for Research and for Routine Diagnostics. In: Biomarkers in Cardiovascular Disease. Patel V, Preedy V. (eds). Springer, Dordrecht. 2015; pp1-17. [Crossref]
5. Thamratnopkoon S, Susantitaphong P, Tumkosit M, Katavetin P, Tiranathanagul K, Praditpornsilpa K, et al. Correlations of Plasma Desphosphorylated Uncarboxylated Matrix Gla Protein with Vascular Calcification and Vascular Stiffness in Chronic Kidney Disease. Nephron. 2017; 135(3):167-172. [PubMed]
6. de Oliveira RB, Stinghen AEM, Massy ZA. Vitamin K role in mineral and bone disorder of chronic kidney disease. Clin Chim Acta. 2020 Mar;502:66-72. [PubMed]
7. Rocco MV, Berns JS. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis. 2012 Nov;60(5):850-86. [PubMed]
8. Hutcheson JD, Goettsch C. Cardiovascular Calcification Heterogeneity in Chronic Kidney Disease. Circ Res. 2023 Apr 14;132(8):993-1012. [Crossref]
9. Torrijo-Belanche C, Moreno-Franco B, Muñoz-Cabrejas A, Calvo-Galiano N, Casasnovas JA, Sayón-Orea C, et al. High Serum Phosphate Is Associated with Cardiovascular Mortality and Subclinical Coronary Atherosclerosis: Systematic Review and Meta-Analysis. Nutrients. 2024 May 24;16(11):1599. [PubMed]
10. Zhou C, Shi Z, Ouyang N, Ruan X. Hyperphosphatemia and Cardiovascular Disease. Front Cell Dev Biol. 2021 Mar 4;9:644363. [PubMed]
11. Griffin TP, Islam MN, Wall D, Ferguson J, Griffin DG, Griffin MD, et al. Plasma dephosphorylated-uncarboxylated Matrix Gla-Protein (dp-ucMGP): reference intervals in Caucasian adults and diabetic kidney disease biomarker potential. Sci Rep. 2019 Dec 1;9(1):18452. [PubMed]
12. Theuwissen E, Magdeleyns EJ, Braam LA, Teunissen KJ, Knapen MH, Binnekamp IA, et al. Vitamin K status in healthy volunteers. Food Funct. 2014 Feb;5(2):229-34. [PubMed]
13. Cranenburg EC, Koos R, Schurgers LJ, Magdeleyns EJ, Schoonbrood TH, Landewé RB, et al. Characterization and potential diagnostic value of circulating matrix Gla protein (MGP) species. Thromb Haemost. 2010 Oct;104(4):811-22. [PubMed]
14. van Ballegooijen AJ, Beulens JWJ, Schurgers LJ, de Koning EJ, Lips P, van Schoor NM, et al. Effect of 6-Month Vitamin D Supplementation on Plasma Matrix Gla Protein in Older Adults. Nutrients. 2019 Jan 22;11(2):231. [PubMed]
15. Levy DS, Grewal R, Le TH. Vitamin K deficiency: an emerging player in the pathogenesis of vascular calcification and an iatrogenic consequence of therapies in advanced renal disease. Am J Physiol - Ren Physiol. 2020 Oct 1;319(4):F618-F623. [ PubMed]
16. Proudfoot D, Shanahan CM. Molecular mechanisms mediating vascular calcification: role of matrix Gla protein. Nephrology (Carlton). 2006 Oct;11(5):455-61. [PubMed]
17. Berkner KL, Runge KW. Vitamin K-Dependent Protein Activation: Normal Gamma-Glutamyl Carboxylation and Disruption in Disease. Int J Mol Sci. 2022 May 20;23(10):5759. [PubMed]
18. Hao Z, Jin DY, Chen X, Schurgers LJ, Stafford DW, Tie JK. γ-Glutamyl carboxylase mutations differentially affect the biological function of vitamin K-dependent proteins. Blood. 2020 Jan 28;137(4):533-543. [PubMed]
19. Galunska B, Yotov Y, Nikolova M, Angelov A. Extrahepatic Vitamin K-Dependent Gla-Proteins – Potential Cardiometabolic Biomarkers. Int J Mol Sci. 2024 Mar 20;25(6):3517. [PubMed]
20. Neofytou IE, Stamou A, Demopoulos A, Roumeliotis S, Zebekakis P, Liakopoulos V, et al. Vitamin K for Vascular Calcification in Kidney Patients: Still Alive and Kicking, but Still a Lot to Learn. Nutrients. 2024 Jun 7;16(12):1798. [PubMed]
21. Jaminon AMG, Dai L, Qureshi AR, Evenepoel P, Ripsweden J, Söderberg M, et al. Matrix Gla protein is an independent predictor of both intimal and medial vascular calcification in chronic kidney disease. Sci Rep. 2020 Apr 20;10(1):6586. [PubMed]
22. Hermans MMH, Vermeer C, Kooman JP, Brandenburg V, Ketteler M, Gladziwa U, et al. Undercarboxylated matrix GLA protein levels are decreased in dialysis patients and related to parameters of calcium-phosphate metabolism and aortic augmentation index. Blood Purif. 2007; 25(5–6):395–401. [PubMed]
Received: 13 December 2024
Published online: 05 May 2025